Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542354 | 1.00 | CHRM1 (0.49) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL3204899 | 0.85 | CHRNA7 (0.53) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL13444720 | 0.82 | CHRNA7 (0.57) | CHRM1CHRM2CHRNA7 | |
| SCHEMBL1542863 | 0.80 | CHRM1 (0.46) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL1542861 | 0.80 | CHRM1 (0.46) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL1542452 | 0.80 | CHRM1 (0.46) | CHRM1CHRM2CHRNA7CHRM4CHRM5 | |
| SCHEMBL14459864 | 0.80 | CHRNA7 (0.55) | CHRM1CHRM2CHRNA7LSS | |
| SCHEMBL14338732 | 0.79 | CHRM1 (0.49) | CHRM1CHRM2CHRNA7 | |
| SCHEMBL13479859 | 0.79 | CHRM1 (0.49) | CHRM1CHRM2CHRNA7 | |
| SCHEMBL13444724 | 0.79 | CHRM1 (0.49) | CHRM1CHRM2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| EP-1824848-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2007-03-15 | — | — | US | disclosed |
| WO-2006065233-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060588-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRM1 22/4885CHRM2 20/4885CHRNA7 2/4885 |
| US-20080064703-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | IDO1, IDO2, HTR3C | CHRM1 698/4885CHRM2 708/4885CHRNA7 144/4885 |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | CHRM1 22/4885CHRM2 20/4885CHRNA7 2/4885 |
| US-20050245531-A1 | 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Down's syndrome; alpha 7 nAChR ligands modulators | CHRNA7, CHRNA6, CHRNA10 | CHRM1 24/4885CHRM2 27/4885CHRNA7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.